跳转至内容
Merck
CN

D0650000

去氨加压素

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C46H64N14O12S2
化学文摘社编号:
分子量:
1069.22
MDL编号:
UNSPSC代码:
41116107
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

pharmaceutical primary standard

API类

desmopressin

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

S1SCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C1)C(=O)N4C(CCC4)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N)Cc3ccccc3)Cc2ccc(cc2)O.OC(=O)C.O.O.O

InChI

1S/C46H64N14O12S2.C2H4O2.3H2O/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25;1-2(3)4;;;/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52);1H3,(H,3,4);3*1H2

InChI key

YNKFCNRZZPFMEX-UHFFFAOYSA-N

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Desmopressin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

PLEASE NOTE: TEMPORARILY UNAVAILABLE DUE TO RESTRICTED QUANTITY

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Tine Olesen et al.
Journal of clinical medicine, 9(7) (2020-07-28)
Nocturia is common and associated with multiple disease states. Many potential mechanisms have been proposed for nocturia, which also remains challenging to manage. To use multivariate analysis to determine which combinations of factors can accurately discriminate clinically significant nocturia in
Peter K Sand et al.
The Journal of urology, 190(3), 958-964 (2013-03-05)
Previous studies suggest a lower dose of desmopressin orally disintegrating tablet may be effective in females compared to males with nocturia. We confirm the efficacy and safety of 25 μg desmopressin orally disintegrating tablet compared to placebo in female patients.
Jeffrey P Weiss et al.
The Journal of urology, 190(3), 965-972 (2013-03-05)
We investigated the efficacy and safety of 50 and 75 μg desmopressin orally disintegrating tablets in men with nocturia (2 or more nocturnal voids). In this 3-month, randomized, double-blind, parallel study 50 and 75 μg desmopressin were compared with placebo.
Patrina Hy Caldwell et al.
The Cochrane database of systematic reviews, 5, CD002911-CD002911 (2020-05-05)
Enuresis (bedwetting) affects up to 20% of five-year-olds and can have considerable social, emotional and psychological effects. Treatments include alarms (activated by urination), behavioural interventions and drugs. To assess the effects of enuresis alarms for treating enuresis in children. We
Nathan T Connell et al.
Blood advances, 5(1), 301-325 (2021-02-12)
von Willebrand disease (VWD) is a common inherited bleeding disorder. Significant variability exists in management options offered to patients. These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持